RxDoctor Payments Data

Kelly Mikesell, PA

Medical · Ogden, UTNPI 1023200888

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.8% of the total across 845 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 7.6% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,921in general payments, 2019–2025

Across 845 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novartis$1K
  • Astellas Pharma US Inc$1K
  • Johnson & Johnson$1K
  • Daiichi Sankyo Inc.$961
  • Incyte Corporation$891
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$17,18791%
  • Education$1,7349%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)62$1,437
Novartis93$1,379
Astellas Pharma US Inc30$1,193
Johnson & Johnson36$1,156
Daiichi Sankyo Inc.45$961
Incyte Corporation30$891
Merck33$675
E.r. Squibb & Sons, L.L.C.25$644
Pfizer46$630
AbbVie26$622
EMD Serono, Inc.22$607
Sanofi21$590
GSK30$473
Amgen19$458
Lilly USA, LLC23$450
Genentech USA, Inc.20$428
Genmab U.S., Inc.16$398
Beigene USA, Inc.9$377
Regeneron Healthcare Solutions, Inc.14$342
Bristol Myers Squibb18$338
Seagen Inc.16$300
Eisai Inc.13$277
Boehringer Ingelheim11$253
Sumitomo Pharma America, Inc.12$248
Takeda Pharmaceuticals U.S.A., Inc.9$207
Pharmaessentia USA Corporation10$188
Gilead(2 entities)9$182
Array Biopharma Inc12$179
Amneal Pharmaceuticals LLC8$175
Sobi, Inc4$148
Coherus Oncology, Inc.6$144
Karyopharm Therapeutics Inc.6$143
Bayer6$114
Tersera Therapeutics LLC5$110
Jazz Pharmaceuticals Inc.6$106
Dendreon Pharmaceuticals LLC1$105
Beone Medicines USA, Inc.4$103
Deciphera Pharmaceuticals Inc.5$97
Rigel Pharmaceuticals, Inc.4$97
Pharmacyclics LLC, An Abbvie Company4$93
Geron Corporation4$83
Immunocore Limited4$82
Azurity Pharmaceuticals, Inc.3$82
Organon5$72
G1 Therapeutics, Inc.3$70
Stemline Therapeutics Inc.3$68
Myovant Sciences Inc.4$67
Servier Pharmaceuticals LLC3$66
Agios Pharmaceuticals, Inc.3$65
Legend Biotech USA Inc.2$64
Springworks Therapeutics, Inc.3$61
Mylan Institutional Inc.2$58
Blueprint Medicines Corporation2$57
Genentech, Inc.1$53
Ipsen Biopharmaceuticals, Inc3$51
Puma Biotechnology, Inc.3$49
Pharmacosmos Therapeutics Inc.3$48
Exelixis Inc.2$36
Helsinn Therapeutics (U.S.), Inc.2$34
Caris MPI, Inc.1$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,921 in reported general payments places this provider in the 95th percentile of 263 medical providers in Utah.

See all medical providers in Utah

Medicare billing

Part B allowed, 2024
$1,428,142
Medicare patients
392
Services billed
87,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib12$140,070
JadenuDeferasirox11$123,716
EliquisApixaban44$36,888
Varenicline Tartrate11$3,306
Potassium Chloride33$1,092
Letrozole48$985
Hydroxyurea29$691
Prochlorperazine Maleate12$645
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$602
Anastrozole33$586
Tamoxifen Citrate20$564
Ondansetron Hcl14$462
Levothyroxine Sodium27$301
Gabapentin20$288
Prednisone24$174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$1,437$140,07012 claims
NovartisJadenu$1,379$123,71611 claims
PfizerEliquis$630$36,88844 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$175$30127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 263 medical providers in Utah.

Other medical in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →